Linked Life Data

19383830

Source:http://linkedlifedata.com/resource/pubmed/id/19383830

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-9-17
pubmed:abstractText
Medullary thyroid carcinoma (MTC) is a rare tumour arising from neural crest-derived parafollicular C-cells. Metastatic MTC patients are incurable because the cancer does not respond to radiotherapy or chemotherapy. The REarranged during Transfection (RET) proto-oncogene plays a key role in the development of MTC. However, one-half of the sporadic MTC do not carry RET mutations. Mice models and early evidence obtained in human samples suggest that other genes, including those encoding components of the RB1 (retinoblastoma) and TP53 tumour-suppressor pathways, may be involved in MTC formation. Here, we review the data on the involvement of genes acting in the RET and RB1/TP53 pathways in MTC. Understanding genetic lesions that occur in MTC is a prerequisite to identifying molecular therapeutic targets in MTC and in improving the efficacy of RET-targeted therapies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1479-6813
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
143-55
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
pubmed:affiliation
Istituto di Endocrinologia ed Oncologia Sperimentale CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, L. Califano, Università Federico II di Napoli, Naples, Italy.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't